



Review:

Nerve growth factor and diarrhea-predominant irritable bowel syndrome (IBS-D): a potential therapeutic target?*

Xiao-juan XU^{1,2}, Liang LIU³, Shu-kun YAO^{†‡1,2}

(¹Gastroenterology Department, China-Japan Friendship Hospital, Beijing 100029, China)

(²Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100073, China)

(³Jinan Central Hospital Affiliated to Shandong University, Jinan 250014, China)

[†]E-mail: Ysk12329@126.com

Received June 27, 2015; Revision accepted Nov. 7, 2015; Crosschecked Dec. 16, 2015

Abstract: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain or discomfort associated with abnormal bowel habits. Diarrhea-predominant IBS (IBS-D) is a major subtype of IBS, the predominant manifestations of which are abdominal pain and diarrhea. The pathogenesis of IBS-D remained unknown until recently. The effects of psychosocial stress, central hypervigilance, neuroendocrine abnormality, disturbed gastrointestinal motility, mucosal immune activation, intestinal barrier dysfunction, visceral hypersensitivity (VH), altered gut flora, and genetic susceptibility may be involved in its development. Recently, increased attention has been placed on the neural-immune-endocrine network mechanism in IBS-D, especially the role of various neuroendocrine mediators. As a member of the neurotrophin family, nerve growth factor (NGF) has diverse biological effects, and participates in the pathogenesis of many diseases. Basic studies have demonstrated that NGF is associated with inflammatory- and stress-related VH, as well as stress-related intestinal barrier dysfunction. The aim of this study is to summarize recent literature and discuss the role of NGF in the pathophysiology of IBS-D, especially in VH and intestinal barrier dysfunction, as well as its potential as a therapeutic target in IBS-D.

Key words: Nerve growth factor, Diarrhea-predominant irritable bowel syndrome, Pathophysiology, Intestinal barrier dysfunction, Visceral hypersensitivity

<http://dx.doi.org/10.1631/jzus.B1500181>

CLC number: R574.4

1 Introduction

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disease without organic abnormalities, characterized by recurrent abdominal pain or discomfort associated with abnormal bowel habits. The diagnosis is established primarily through symptoms according to the Rome III criteria of 2006, after exclusion of organic gastrointestinal diseases through endoscopy, radiology, and other biochem-

ical tests. Epidemiological surveys show that the prevalence of IBS in China is between 1% and 16% (Zhang *et al.*, 2014), while the prevalence in the western population is relatively high, ranging from 10% to 18% (Choung and Locke, 2011). As a major subtype, diarrhea-predominant IBS (IBS-D) accounts for 23.3%–65% of IBS cases (Yao *et al.*, 2008; Shen *et al.*, 2011), and its predominant clinical manifestations are abdominal pain and diarrhea. The recurrent and distressing abdominal symptoms, always accompanied by psychological disorders, affect the patients' quality of life to varying degrees.

The pathogenesis of IBS-D has not been completely understood until recently. The effects of psychosocial stress, central hypervigilance, neuroendocrine abnormality, disturbed gastrointestinal motility,

[‡] Corresponding author

* Project supported by the National Ministry of Science and Technology "Twelfth Five-Year" Supporting Project (No. 2014BAI08B02), China

ORCID: Xiao-juan XU, <http://orcid.org/0000-0002-3797-0567>

© Zhejiang University and Springer-Verlag Berlin Heidelberg 2016

mucosal immune activation, intestinal barrier dysfunction, visceral hypersensitivity (VH), altered gut flora, as well as genetic susceptibility, may be involved in its development (Camilleri, 2012). A single factor cannot fully explain the pathogenesis and symptoms of IBS-D. These factors may have complex interactions and their positions may vary in the pathogenesis of the disorder in the individual IBS-D patient, resulting in heterogeneity of IBS-D.

Recently, a neural-immune-endocrine network mechanism has gained increasing attention, especially relating to the role of various neuroendocrine mediators, such as serotonin (5-HT), substance P (SP), brain derived neurotrophic factor (BDNF), and nerve growth factor (NGF) in IBS-D. This article will review the literature on the role of NGF in the pathophysiology of IBS-D, especially in VH and intestinal barrier dysfunction.

Publications related to IBS and NGF in both the English and Chinese languages were searched in PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure (CNKI), Weipu, and Wanfang databases from their inception to May 2015

(Fig. 1). The initial literature search identified a total of 1274 citations. After removal of duplicates, 1161 records were left; and among these, 738 records were excluded based on their titles and abstracts. Full-text examinations further excluded 364 records because of irrelevance to the aim of the present study. Finally, 59 eligible records were identified and included in this study, consisting of 15 literature reviews, 15 animal researches, and 29 human researches.

2 What is NGF?

Neurotrophins (NTs) are a family of trophic factors that regulate the growth, function, plasticity, survival, and apoptosis of neurons, including NGF, BDNF, NT-3, and NT-4 (Bothwell, 2014). Secreted by various tissues and cells, such as innervated tissues, astrocytes, mast cells, and epithelial cells, NTs will enter nerve endings in a receptor-mediated manner, and are then backwards transported to the cell body of the neuron to modulate the synthesis of the related proteins. Recent studies have found that NTs and their




Fig. 1 Flow diagram of the study selection and exclusion process

receptors are widely distributed in the digestive tract, and exert important effects on the sensation, motility, and secretion of the digestive tract.

As the first member discovered in the NT family, NGF is a multimeric protein consisting of subunits α , β , and γ , of which β is the active subunit. NGF is distributed in various organs, such as the brain, ganglion, skeletal muscle, intestine, bladder, etc. NGF exerts its functions via two membrane receptors: a high-affinity receptor TrkA and a low-affinity receptor p75^{NTR} (Wang and Wu, 2010), and the former is of particular importance. The main biological effects of NGF include promoting neuronal differentiation, stimulating the growth of dendrites and cell bodies, and affecting nerve fiber density. In addition, NGF plays a regulatory role in the function of non-nerve tissues, such as the activation, proliferation, and

apoptosis of mast cells, lymphocytes, and epithelial cells. Under acute or chronic stress, tissue damage, inflammation, and other pathological conditions, increased NGF can change the local nerve fiber plasticity, resulting in hyperalgesia, as well as organ dysfunction (Lewin et al., 2014).

There is very limited clinical evidence on the relationship between NGF and IBS-D. However, basic studies have demonstrated that NGF is associated with inflammatory- and stress-related VH, as well as stress-related intestinal barrier dysfunction. Due to the existence of stress and low-grade mucosal inflammation in IBS-D, NGF may play a potential role in the pathophysiology of IBS-D, particularly in VH and intestinal barrier dysfunction. Detailed information of the individual studies exploring the role of NGF in IBS pathophysiology is presented in Table 1.

Table 1 Key data from the various studies exploring the role of NGF in IBS pathophysiology

Reference	Country	Study type	Employed techniques	Key findings
Willot et al., 2012	Canada	Human	Immunohistochemistry, enzyme-linked immunosorbent assay (ELISA)	Rectal mucosal NGF content was higher in IBS-D children than in control and correlated with mast cell (MC) number
Dothel et al., 2015	Italy	Human	Immunohistochemistry, ELISA, primary cell culture, qRT-PCR	Higher nerve fiber density, neuronal sprouting, and mucosal NGF and TrkA levels in IBS patients; NGF antibodies inhibited the neurotrophic effect of mucosal supernatants from IBS patients
Barreau et al., 2004	France	Animal	Immunohistochemistry, RT-PCR, gut permeability (GP) by ⁵¹ Cr-EDTA	Maternal deprivation (MD) increased visceral sensitivity, GP, and colonic NGF expression in rats; NGF antibodies abolished these effects
van den Wijngaard, 2009	The Netherlands	Animal	Immunohistochemistry, qRT-PCR, Western blotting	Acute stress induced colonic hypersensitivity and elevated colonic MC numbers in adult MD rats; MC stabilizer, NGF antibodies, or TRPV1 antagonist prevented the hypersensitivity
Yu et al., 2008	China	Animal	Intraperitoneal NGF injection	NGF enhanced water avoidance (WA)-induced visceral hypersensitivity
Delafoy et al., 2003	France	Animal	Intraperitoneal NGF injection	Both NGF and trinitrobenzene sulfonic acid (TNBS) induced colonic hypersensitivity via capsaicin-sensitive afferent fibers; NGF antibodies could reverse the effects of NGF and TNBS
Delafoy et al., 2006	France	Animal	Drug intervention, colonic sensitivity assessment via barostat	Calcitonin gene-related peptide (CGRP) antagonist alleviated TNBS or NGF-induced colonic hypersensitivity; NGF antibodies failed to reverse CGRP-induced hypersensitivity
Barreau et al., 2007	France	Animal	Drug intervention, GP by ⁵¹ Cr-EDTA, immunohistochemistry, ELISA	MD rats showed increased GP and colonic NGF content; CRF acts on mast cells to stimulate NGF release and participates in the elevated GP observed in MD adult rats
Barreau et al., 2008	France	Animal	Immunohistochemistry, ELISA, drug intervention	MD induced increased nerve fiber density and synaptogenesis, as well as mast cell hyperplasia and hypertrophy; NGF antibodies prevented these effects

3 NGF and VH in IBS-D

VH is a clinical marker in a subset of IBS-D patients, and contributes to abdominal pain, bloating, urgency, and other symptoms. VH is defined as increased visceral sensitivity to mechanical, temperature, chemical, and other stimuli; a balloon distension test shows decreased rectal sensory thresholds compared with healthy individuals. It is a widely accepted fact that the mechanisms of VH involve multiple levels of the nervous system: sensory nerve endings, spinal afferent pathways, and the brain. In addition, neuroendocrine mediators, gut flora, and low-grade mucosal inflammation are also involved (Zhou and Li, 2014). An increasing number of clinical and basic studies have confirmed that NGF is closely related to VH.

3.1 Clinical studies on NGF and VH in IBS

Akbar *et al.* (2008) reported increased SP-positive and transient receptor potential vanilloid 1 (TRPV1)-positive nerve fibers in colonic mucosa of IBS patients, and a positive correlation between TRPV1 staining intensity and abdominal pain, speculating that in the low-grade inflamed mucosa of IBS, elevated NGF mediates TRPV1 up-regulation and leads to VH. However, this research lacks direct evidence of the NGF level in IBS. Willot *et al.* (2012) first determined NGF in rectal mucosa of IBS-D children by enzyme-linked immunosorbent assay (ELISA) testing, and observed elevated NGF content compared with healthy controls. Recently, Dothel *et al.* (2015) discovered increased density of neuronal-specific enolase (NSE)-positive and growth associated protein 43 (GAP43)-positive fibers in the colonic mucosa from IBS patients, indicating higher nerve fiber density and neuronal sprouting; mucosal NGF and TrkA levels were also increased in IBS patients; mucosal supernatants from these patients promoted neurogenesis of human neuronal cell lines, which could be inhibited by anti-NGF antibodies. These results indicate that increased NGF acts on the intestinal sensory nerve endings, promotes their growth and synapse formation, and thus mediates VH. Limitations of these studies are that correlations between elevated NGF and visceral sensitivity indicators, as well as IBS symptoms, have not been analyzed. These issues deserve further investigation to clarify the role of NGF in the pathogenesis of IBS-D.

3.2 Mechanisms of NGF-mediated VH

In inflammatory diseases and animal models, by modifying neuronal plasticity, NGF promotes the perception and transduction of inflammatory pain, and mediates hypersensitivity of the related tissues and organs. For instance, colonic NGF and TrkA expression were increased in inflammatory bowel disease (IBD) patients (di Mola *et al.*, 2000), and the NGF level in ulcerative colitis was positively correlated with the severity of the disease (Li *et al.*, 2014). In rat models of chemically-induced cystitis, rats exhibited inflammatory bladder pain, skin mechanical hypersensitivity, and increased NGF content in the bladder mucosa; administration of TrkA antagonist before modeling prevented bladder and skin hyperalgesia, suggesting that coupled with TrkA, NGF transmits signals to the sensory neurons, activates pain pathway, and mediates hypersensitivity (Coelho *et al.*, 2015).

Stress animal models present similar pathophysiologic abnormalities to that in IBS patients, such as VH and intestinal barrier dysfunction. Therefore, these experimental models are always used to explore the pathophysiology of IBS. NGF-mediated VH is not restricted to the inflammatory state, but also is involved in the stress state. Barreau *et al.* (2004) reported NGF to be an important mediator in neonatal maternal deprivation (MD)-induced VH. After experiencing MD for several weeks, the rats showed VH to rectal distention and elevated colonic NGF; treatment with anti-NGF antibodies during MD abolished MD-induced hypersensitivity. Another study showed that acute water avoidance (WA) stress induced hypersensitivity to colonic distention in adult MD rats, and also caused a slight increase in the colonic mast cell (MC) numbers, but not in non-MD rats; administration of MC stabilizer, anti-NGF antibody, or TRPV1 antagonist before WA prevented hypersensitivity (van den Wijngaard *et al.*, 2009). Yu *et al.* (2008) showed that intraperitoneal injection of NGF enhanced WA-induced VH, through the up-regulation of TRPV1. This evidence suggests that NGF, MC, and TRPV1 are involved in stress-related VH, and the cascade sequence may be as follows: stress-MC-NGF-TRPV1-VH.

Administration of exogenous NGF to normal tissues induces hypersensitivity similar to that in inflammation and stress. Rukwied *et al.* (2010) injected

1 µg NGF into a normal human forearm and induced local temperature and mechanical hypersensitivity. Delafoy *et al.* (2003; 2006) showed that intraperitoneal injection of NGF lowered colonic distention thresholds in rats, which could be reversed by anti-NGF antibodies or a calcitonin gene-related peptide (CGRP) antagonist; injection of CGRP also induced similar hypersensitivity, while anti-NGF antibodies failed to reverse it, indicating that CGRP is a critical element downstream in NGF signaling; if capsaicin-sensitive C-fiber afferents were damaged during the neonatal period, then NGF-induced colonic hypersensitivity was abolished.

Taken together, the possible mechanisms of NGF-mediated VH are that NGF causes neurotrophic effects on sensory nerve endings, promoting the proliferation of SP-, CGRP-, and TRPV1-positive nociceptive fibers; moreover, NGF modulates the activation state of nociceptor proteins such as TRPV1 to sensitize the nerve endings (Bonnington and McNaughton, 2003; Zhuang *et al.*, 2004; Zhu and Oxford, 2007); NGF is also backwards transported to the cell body in the dorsal root ganglia (DRG), increasing the TRPV1 expression and translocation to the peripheral terminals (Stein *et al.*, 2006). All these lead to hypersensitivity of the sensory nerve endings, increased release of pain-related peptides (such as CGRP, SP) after stimulation, and subsequent hyperalgesia.

4 NGF and intestinal barrier dysfunction in IBS-D

Intact intestinal barrier defense relies on three components: pre-epithelium, epithelium, and post-epithelium (Hao and Duan, 2010). The pre-epithelium component includes the mucus and microbiota, together with chemical substances such as cytokines, inflammatory mediators, and antimicrobial peptides. The epithelium plays a critical role in the intestinal barrier function, and primarily consists of intestinal epithelial cells and intercellular tight junctions (TJs). The post-epithelium component includes immunocytes in lamina propria, blood vessels, and the enteric nervous system (ENS) (Keita and Söderholm, 2010; Bischoff *et al.*, 2014). It is now an accepted fact that intestinal barrier dysfunction plays a pathogenic role in IBS-D, which manifests itself as increased mucosal permeability, ultrastructural alteration of the TJ, an

abnormal level of TJ-related proteins and other associated blood markers.

4.1 Evidence of intestinal barrier dysfunction in IBS-D

Several studies observed increased intestinal permeability in IBS patients via the oral multi-sugar test (Mujagic *et al.*, 2014; Shulman *et al.*, 2014). A study on IBS-D patients performed by Liu *et al.* (2014) showed elevated urinary levels of I-FABP, I-BABP, and L-FABP, which are regarded as clear markers of intestinal barrier function. Lee *et al.* (2013) confirmed increased intestinal permeability in IBS-D using an Ussing chamber. Martínez *et al.* (2013) observed abnormalities in the expression, phosphorylation, and distribution of TJ-related proteins (such as claudin and occludin), as well as disrupted ultrastructure of the intercellular apical junction complex (AJC) in the jejunal mucosa of IBS-D patients, revealing the underlying molecular and structural basis of intestinal barrier dysfunction in IBS-D.

4.2 Mechanisms of NGF-mediated barrier dysfunction

The neonatal MD model is usually used to mimic the intestinal barrier dysfunction in IBS patients. Barreau *et al.* (2004; 2007) reported that NGF was a key factor in MD-induced intestinal barrier dysfunction. In that study, MD rats presented increased intestinal permeability measured by ⁵¹Cr-EDTA excretion, as well as elevated MC numbers and NGF expression; MD rats administered anti-NGF antibodies showed normal permeability; the intraperitoneal injection of NGF induced similar changes in permeability and the MC numbers in non-MD rats. Possible explanation is that stress promotes intestinal NGF expression. Increased NGF acts on MCs and promotes their proliferation, activation, and release of mediators (Barreau *et al.*, 2008). Various MC-derived mediators (such as tryptase, histamine, prostaglandins, interleukin (IL)-4, IL-10, and tumor necrosis factor (TNF)-α) combine with specific membrane receptors on epithelial cells, and modify the expression and location of TJ proteins, resulting in increased intestinal permeability. NGF can not only indirectly affect permeability via MC, but also act on intestinal epithelial cells via its receptor TrkA, and directly change permeability. Due to increased intestinal permeability, exposure of submucosal tissue to antigens such as

intraluminal pathogens occurs more frequently, overstimulating the local immune system. Various immune and inflammatory mediators activate intestinal receptors and cause disturbances in sensation, motility, and secretion in the digestive tract, contributing to the symptoms of IBS-D (Piche *et al.*, 2009; Zhou *et al.*, 2009).

As mentioned above, evidence of numerous basic researches has demonstrated the critical role of NGF in stress-related intestinal barrier dysfunction. Stress is involved in the pathogenesis of IBS-D, and is a trigger of IBS symptoms. Thus, it can be assumed that NGF participates in intestinal barrier dysfunction in IBS-D patients, which remains to be confirmed by further studies.

5 NGF-MC-nerve interaction in IBS-D pathophysiology

Intestinal MC is regarded as the key component of the neural-immune-endocrine network mechanism in IBS-D, and also the main source of NGF in the intestinal mucosa (Leon *et al.*, 1994; Levi-Montalcini *et al.*, 1996; Skaper *et al.*, 2001). MCs are always adjacent to small-diameter unmyelinated nerve fibers that are primarily peptidergic fibers containing neuropeptides such as SP and CGRP, and can respond to noxious stimuli and induce pain (Park *et al.*, 2003; Barbara *et al.*, 2004). Moreover, these fibers express TrkA and receive regulation of NGF (Snider and McMahon, 1998). These spacial and structural features suggest functional interaction of the NGF-MC-nerve.

In the pathogenesis of IBS-D (Fig. 2), psychophysiological stress (such as adverse life events, catching cold, and intestinal infection) activates the hypothalamic-pituitary-adrenal (HPA) axis (Mayer, 2000; Chang *et al.*, 2009; Kennedy *et al.*, 2014). The central and intestinal corticotropin releasing factor (CRF) increases and activates intestinal MCs (Barreau *et al.*, 2007; Overman *et al.*, 2012). Activated MCs degranulate and release mediators such as NGF and tryptase. These mediators act on intestinal epithelial cells, and influence the expression and localization of TJ proteins, resulting in increased intestinal permeability and intestinal barrier dysfunction (Ferrer *et al.*, 2003; Cenac *et al.*, 2007; Coëffier *et al.*, 2010). In addition, the ENS, especially the VIPergic submucosal nerve fibers, has been demonstrated to

regulate the expression of TJ-related proteins (such as ZO-1) and affect the intestinal barrier homeostasis. Thus, in addition to the MC-related mechanism, NGF may modulate the barrier function via ENS and its neuropeptides (such as vasoactive intestinal peptide (VIP)) (Neunlist *et al.*, 2003).




Fig. 2 NGF-MC-nerve interaction in IBS-D pathophysiology

With respect to VH, MC-derived mediators such as tryptase, NGF, histamine, 5-HT, and prostaglandins activate the intestinal sensory nerve endings (Barbara *et al.*, 2007; Ohashi *et al.*, 2008). Moreover, as a neurotrophic factor, NGF modifies local neuronal plasticity, leading to changes in the distribution of sensory nerve endings, expression and location of nociceptor proteins (such as TRPV1), and the release of neuropeptides (such as SP, CGRP, VIP). All these factors cause hypersensitivity of the sensory nerve endings to noxious and even physiological stimuli, which forms the foundation of VH.

In addition, MC-derived NGF can act on the MC in a paracrine or autocrine manner. Likewise, sensory nerve endings, activated by MC mediators, can release neuropeptides to affect the MC. All these in turn will promote MC activation and NGF production, forming the positive feedback loop.

Intestinal barrier dysfunction and VH caused by NGF-MC-nerve interaction constitute the pathophysiological basis of IBS-D symptoms, such as abdominal pain and diarrhea.

6 Conclusions and prospects

IBS has always been considered a functional gastrointestinal disease, without the clear evidence of

any organic gastrointestinal diseases. However, it is a general rule in most diseases that there are always structural or organic abnormalities underlying the functional alterations. Many efforts have been made to seek the underlying culprits of IBS symptoms, but the pathophysiology of IBS-D is still not entirely understood, leading to a lack of specific and effective therapy.

The neural-immune-endocrine network mechanism has become a hot spot for research at present. NGF, as an important neuroendocrine mediator, presents diverse biological and pathological effects. Its relationship with visceral sensitivity and the intestinal barrier function, as well as mobility, gut flora, mental condition, and the genetic background of IBS-D patients, deserves further investigation, in order to elucidate the pathophysiology of IBS-D.

In disease management, NGF-targeted therapy has shown encouraging prospects in several illnesses. For instance, with the clarification of the role NGF plays in chronic inflammatory pain, researchers evaluated the efficacy of anti-NGF therapy in chronic pain associated with osteoarthritis (Sanga *et al.*, 2013; Tiseo *et al.*, 2014), interstitial cystitis (Evans *et al.*, 2011), diabetic neuropathy (Bramson *et al.*, 2015), chronic pelvic pain syndrome (Nickel *et al.*, 2012), and chronic low back pain (Gimbel *et al.*, 2014), and the results were optimistic. Given that chronic abdominal pain is one of the main manifestations of IBS-D, it is worth further investigation as to whether anti-NGF therapy could show similar optimistic results in IBS-related abdominal pain, as well as other symptoms. In the future, NGF may be a promising therapeutic target in IBS-D.

Compliance with ethics guidelines

Xiao-juan XU, Liang LIU, and Shu-kun YAO declare that they have no conflict of interest.

This paper does not contain any studies with human or animal subjects performed by any of the authors.

References

- Akbar, A., Yiangou, Y., Facer, P., *et al.*, 2008. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. *Gut*, **57**(7):923-929. <http://dx.doi.org/10.1136/gut.2007.138982>
- Barbara, G., Stanghellini, V., de Giorgio, R., *et al.*, 2004. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology*, **126**(3):693-702. <http://dx.doi.org/10.1053/j.gastro.2003.11.055>
- Barbara, G., Wang, B., Stanghellini, V., *et al.*, 2007. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. *Gastroenterology*, **132**(1):26-37. <http://dx.doi.org/10.1053/j.gastro.2006.11.039>
- Barreau, F., Cartier, C., Ferrier, L., *et al.*, 2004. Nerve growth factor mediates alterations of colonic sensitivity and mucosal barrier induced by neonatal stress in rats. *Gastroenterology*, **127**(2):524-534. <http://dx.doi.org/10.1053/j.gastro.2004.05.019>
- Barreau, F., Cartier, C., Leveque, M., *et al.*, 2007. Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay. *J. Physiol.*, **580**(1):347-356. <http://dx.doi.org/10.1113/jphysiol.2006.120907>
- Barreau, F., Salvador-Cartier, C., Houdeau, E., *et al.*, 2008. Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats. *Gut*, **57**(5):582-590. <http://dx.doi.org/10.1136/gut.2007.126680>
- Bischoff, S.C., Barbara, G., Buurman, W., *et al.*, 2014. Intestinal permeability—a new target for disease prevention and therapy. *BMC Gastroenterol.*, **14**(1):189. <http://dx.doi.org/10.1186/s12876-014-0189-7>
- Bonnington, J.K., McNaughton, P.A., 2003. Signalling pathways involved in the sensitisation of mouse nociceptive neurons by nerve growth factor. *J. Physiol.*, **551**(2):433-446. <http://dx.doi.org/10.1113/jphysiol.2003.039990>
- Bothwell, M., 2014. NGF, BDNF, NT3, and NT4. In: Lewin, G.R., Carter, B.D. (Eds.), *Neurotrophic Factors*. Springer Berlin Heidelberg, p.3-15. http://dx.doi.org/10.1007/978-3-642-45106-5_1
- Bramson, C., Herrmann, D.N., Carey, W., *et al.*, 2015. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. *Pain Med.*, **16**(6):1163-1176. <http://dx.doi.org/10.1111/pme.12677>
- Camilleri, M., 2012. Peripheral mechanisms in irritable bowel syndrome. *N. Engl. J. Med.*, **367**(17):1626-1635. <http://dx.doi.org/10.1056/NEJMra1207068>
- Cenac, N., Andrews, C.N., Holzhausen, M., *et al.*, 2007. Role for protease activity in visceral pain in irritable bowel syndrome. *J Clin. Invest.*, **117**(3):636-647. <http://dx.doi.org/10.1172/JCI29255>
- Chang, L., Sundaresh, S., Elliott, J., *et al.*, 2009. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. *Neurogastroenterol. Motil.*, **21**(2):149-159. <http://dx.doi.org/10.1111/j.1365-2982.2008.01171.x>
- Choung, R.K., Locke, G.R., 2011. Epidemiology of IBS. *Gastroenterol. Clin. N. Am.*, **40**(1):1-10. <http://dx.doi.org/10.1016/j.gtc.2010.12.006>
- Coëffier, M., Gloro, R., Boukhettala, N., *et al.*, 2010. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. *Am. J. Gastroenterol.*, **105**(5):1181-1188. <http://dx.doi.org/10.1038/ajg.2009.700>
- Coelho, A., Wolf-Johnston, A.S., Shinde, S., *et al.*, 2015. Urinary bladder inflammation induces changes in

- urothelial nerve growth factor and vanilloid receptor 1. *Br. J. Pharmacol.*, **172**(7):1691-1699.
<http://dx.doi.org/10.1111/bph.12958>
- Delafoy, L., Raymond, F., Doherty, A.M., et al., 2003. Role of nerve growth factor in the trinitrobenzene sulfonic acid-induced colonic hypersensitivity. *Pain*, **105**(3):489-497.
[http://dx.doi.org/10.1016/S0304-3959\(03\)00266-5](http://dx.doi.org/10.1016/S0304-3959(03)00266-5)
- Delafoy, L., Gelot, A., Ardid, D., et al., 2006. Interactive involvement of brain derived neurotrophic factor, nerve growth factor, and calcitonin gene related peptide in colonic hypersensitivity in the rat. *Gut*, **55**(7):940-945.
<http://dx.doi.org/10.1136/gut.2005.064063>
- di Mola, F.F., Friess, H., Zhu, Z.W., et al., 2000. Nerve growth factor and Trk high affinity receptor (*TrkA*) gene expression in inflammatory bowel disease. *Gut*, **46**(5):670-678.
<http://dx.doi.org/10.1136/gut.46.5.670>
- Dothel, G., Barbaro, M.R., Boudin, H., et al., 2015. Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. *Gastroenterology*, **148**(5):1002-1011.
<http://dx.doi.org/10.1053/j.gastro.2015.01.042>
- Evans, R.J., Moldwin, R.M., Cossons, N., et al., 2011. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. *J. Urol.*, **185**(5):1716-1721.
<http://dx.doi.org/10.1016/j.juro.2010.12.088>
- Ferrier, L., Mazelin, L., Cenac, N., et al., 2003. Stress-induced disruption of colonic epithelial barrier: role of interferon- γ and myosin light chain kinase in mice. *Gastroenterology*, **125**(3):795-804.
[http://dx.doi.org/10.1016/S0016-5085\(03\)01057-6](http://dx.doi.org/10.1016/S0016-5085(03)01057-6)
- Gimbel, J.S., Kivitz, A.J., Bramson, C., et al., 2014. Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain. *Pain*, **155**(9):1793-1801.
<http://dx.doi.org/10.1016/j.pain.2014.06.004>
- Hao, J.X., Duan, L.P., 2010. Progress in the relationship of intestinal mucosal barrier function and irritable bowel syndrome. *Chin. J. Dig.*, **30**(11):861-863 (in Chinese).
<http://dx.doi.org/10.3760/cma.j.issn.0254-1432.2010.11.026>
- Keita, A.V., Söderholm, J.D., 2010. The intestinal barrier and its regulation by neuroimmune factors. *Neurogastroenterol. Motil.*, **22**(7):718-733.
<http://dx.doi.org/10.1111/j.1365-2982.2010.01498.x>
- Kennedy, P.J., Cryan, J.F., Quigley, E.M., et al., 2014. A sustained hypothalamic-pituitary-adrenal axis response to acute psychosocial stress in irritable bowel syndrome. *Psychol. Med.*, **44**(14):3123-3134.
<http://dx.doi.org/10.1017/S003329171400052X>
- Lee, H., Park, J.H., Park, D.I., et al., 2013. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome. *J. Neurogastroenterol. Motil.*, **19**(2):244-250.
<http://dx.doi.org/10.5056/jnm.2013.19.2.244>
- Leon, A., Buriani, A., Dal Toso, R., et al., 1994. Mast cells synthesize, store, and release nerve growth factor. *PNAS*, **91**(9):3739-3743.
<http://dx.doi.org/10.1073/pnas.91.9.3739>
- Levi-Montalcini, R., Skaper, S.D., Dal Toso, R., et al., 1996. Nerve growth factor: from neurotrophin to neurokine. *Trends Neurosci.*, **19**(11):514-520.
[http://dx.doi.org/10.1016/S0166-2236\(96\)10058-8](http://dx.doi.org/10.1016/S0166-2236(96)10058-8)
- Lewin, G.R., Lechner, S.G., Smith, E.S., 2014. Nerve growth factor and nociception: from experimental embryology to new analgesic therapy. In: Lewin, G.R., Carter, B.D. (Eds.), *Neurotrophic Factors*. Springer Berlin Heidelberg, p.251-282.
http://dx.doi.org/10.1007/978-3-642-45106-5_10
- Li, Q., Xu, C.P., Yang, M., et al., 2014. Expression and significance of nerve growth factor in ulcerative colitis. *Chin. J. Gastroenterol.*, **19**(10):593-595 (in Chinese).
<http://dx.doi.org/10.3969/j.issn.1008-7125.2014.10.004>
- Liu, L., Liu, B.N., Chen, S., et al., 2014. Visceral and somatic hypersensitivity, autonomic cardiovascular dysfunction and low-grade inflammation in a subset of irritable bowel syndrome patients. *J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.)*, **15**(10):907-914.
<http://dx.doi.org/10.1631/jzus.B1400143>
- Martínez, C., Lobo, B., Pigrau, M., et al., 2013. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. *Gut*, **62**(8):1160-1168.
<http://dx.doi.org/10.1136/gutjnl-2012-302093>
- Mayer, E.A., 2000. The neurobiology of stress and gastrointestinal disease. *Gut*, **47**(6):861-869.
<http://dx.doi.org/10.1136/gut.47.6.861>
- Mujagic, Z., Ludidi, S., Keszthelyi, D., et al., 2014. Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. *Aliment. Pharmacol. Ther.*, **40**(3):288-397.
<http://dx.doi.org/10.1111/apt.12829>
- Neunlist, M., Toumi, F., Oreschkova, T., et al., 2003. Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways. *Am. J. Physiol. Gastrointest. Liver Physiol.*, **285**(5):G1028-G1036.
<http://dx.doi.org/10.1152/ajpgi.00066.2003>
- Nickel, J.C., Atkinson, G., Krieger, J.N., et al., 2012. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. *Urology*, **80**(5):1105-1110.
<http://dx.doi.org/10.1016/j.urology.2012.07.035>
- Ohashi, K., Sato, Y., Kawai, M., et al., 2008. Abolishment of TNBS-induced visceral hypersensitivity in mast cell deficient rats. *Life Sci.*, **82**(7-8):419-423.
<http://dx.doi.org/10.1016/j.lfs.2007.11.027>
- Overman, E.L., Rivier, J.E., Moeser, A.J., 2012. CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF- α . *PLoS ONE*, **7**(6):e39935.
<http://dx.doi.org/10.1371/journal.pone.0039935>
- Park, C.H., Joo, Y.E., Choi, S.K., 2003. Activated mast cell infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome. *J. Korean Med. Sci.*, **18**(2):204-210.
<http://dx.doi.org/10.3346/jkms.2003.18.2.204>
- Piche, T., Barbara, G., Aubert, P., et al., 2009. Impaired intestinal barrier integrity in the colon of patients with

- irritable bowel syndrome: involvement of soluble mediators. *Gut*, **58**(2):196-201.
<http://dx.doi.org/10.1136/gut.2007.140806>
- Rukwied, R., Mayer, A., Kluschina, O., et al., 2010. NGF induces non-inflammatory localized and lasting mechanical and thermal hypersensitivity in human skin. *Pain*, **148**(3):407-413.
<http://dx.doi.org/10.1016/j.pain.2009.11.022>
- Sanga, P., Katz, N., Polverejan, E., et al., 2013. Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. *Pain*, **154**(10):1910-1919.
<http://dx.doi.org/10.1016/j.pain.2013.05.051>
- Shen, F., Li, D.G., Zhou, H.Q., 2011. An epidemiological investigation of irritable bowel syndrome in Shanghai Songjiang communities. *Chin. J. Dig.*, **31**(10):663-668 (in Chinese). <http://dx.doi.org/10.3760/cma.j.issn.0254-1432.2011.10.005>
- Shulman, R.J., Jarrett, M.E., Cain, K.C., et al., 2014. Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. *J. Gastroenterol.*, **49**(11):1467-1476.
<http://dx.doi.org/10.1007/s00535-013-0919-6>
- Skaper, S.D., Pollock, M., Facci, L., 2001. Mast cells differentially express and release active high molecular weight neurotrophins. *Mol. Brain Res.*, **97**(2):177-185.
[http://dx.doi.org/10.1016/S0169-328X\(01\)00314-X](http://dx.doi.org/10.1016/S0169-328X(01)00314-X)
- Snider, W.D., McMahon, S.B., 1998. Tackling pain at the source: new ideas about nociceptors. *Neuron*, **20**(4):629-632.
[http://dx.doi.org/10.1016/S0896-6273\(00\)81003-X](http://dx.doi.org/10.1016/S0896-6273(00)81003-X)
- Stein, A.T., Ufret-Vincenty, C.A., Hua, L., et al., 2006. Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane. *J. Gen. Physiol.*, **128**(5):509-522.
<http://dx.doi.org/10.1085/jgp.200609576>
- Tiseo, P.J., Kivitz, A.J., Ervin, J.E., et al., 2014. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. *Pain*, **155**(7):1245-1252.
<http://dx.doi.org/10.1016/j.pain.2014.03.018>
- van den Wijngaard, R.M., Klooker, T.K., Welting, O., et al., 2009. Essential role for TRPV1 in stress-induced (mast cell-dependent) colonic hypersensitivity in maternally separated rats. *Neurogastroenterol. Motil.*, **21**(10):1107-e94.
<http://dx.doi.org/10.1111/j.1365-2982.2009.01339.x>
- Wang, W.L., Wu, W.C., 2010. Nerve growth factor and irritable bowel syndrome. *Chin. J. Gastroenterol. Hepatol.*, **19**(3):285-287 (in Chinese).
<http://dx.doi.org/10.3969/j.issn.1006-5709.2010.03.029>
- Willot, S., Gauthier, C., Patey, N., et al., 2012. Nerve growth factor content is increased in the rectal mucosa of children with diarrhea-predominant irritable bowel syndrome. *Neurogastroenterol. Motil.*, **24**(8):734-e347.
<http://dx.doi.org/10.1111/j.1365-2982.2012.01933.x>
- Yao, X., Yang, Y.S., Zhao, K.B., et al., 2008. Clinical features and subtypes of irritable bowel syndrome based on Rome III diagnostic criteria. *World Chin. J. Digestol.*, **16**(5):563-566 (in Chinese).
<http://dx.doi.org/10.3969/j.issn.1009-3079.2008.05.023>
- Yu, Y., Gao, J., Zhang, W., et al., 2008. Effect of nerve growth factor on colorectal visceral hypersensitivity in rats. *Chin. J. Dig.*, **28**(11):764-766 (in Chinese).
<http://dx.doi.org/10.3760/j.issn.0254-1432.2008.11.011>
- Zhang, L., Duan, L.P., Liu, Y.X., et al., 2014. A meta-analysis of the prevalence and risk factors of irritable bowel syndrome in Chinese community. *Chin. J. Intern. Med.*, **53**(12):969-975 (in Chinese).
<http://dx.doi.org/10.3760/cma.j.issn.0578-1426.2014.12.011>
- Zhou, Q.Q., Zhang, B.Y., Verne, G.N., 2009. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. *Pain*, **146**(1-2):41-46.
<http://dx.doi.org/10.1016/j.pain.2009.06.017>
- Zhou, X.P., Li, X.L., 2014. Advances in studies on visceral hypersensitivity of irritable bowel syndrome. *Chin. J. Gastroenterol.*, **19**(2):117-119 (in Chinese).
<http://dx.doi.org/10.3969/j.issn.1008-7125.2014.02.011>
- Zhu, W., Oxford, G.S., 2007. Phosphoinositide-3-kinase and mitogen activated protein kinase signaling pathways mediate acute NGF sensitization of TRPV1. *Mol. Cell. Neurosci.*, **34**(4):689-700.
<http://dx.doi.org/10.1016/j.mcn.2007.01.005>
- Zhuang, Z.Y., Xu, H., Clapham, D.E., et al., 2004. Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. *J. Neurosci.*, **24**(38):8300-8309.
<http://dx.doi.org/10.1523/JNEUROSCI.2893-04.2004>

中文概要

题目: 神经生长因子与腹泻型肠易激综合征: 具有前景的治疗靶点?

目的: 回顾国内外研究进展, 针对神经生长因子 (NGF) 在腹泻型肠易激综合征 (IBS-D) 病理生理学, 尤其在内脏高敏感和肠屏障功能受损中的作用作一综述。

创新点: 总结了国内外有关 NGF 参与 IBS-D 病理生理学的基础及临床研究证据, 提出了 NGF 介导 IBS-D 内脏高敏感和肠屏障功能受损的可能机制, 并首次构建了 NGF-肥大细胞-神经纤维三者在 IBS-D 发病中的作用网络。

方法: 在 PubMed、EMBASE、Web of Science、CNKI、维普和万方等数据库检索有关 NGF 参与 IBS-D 病理生理学的中英文文献, 时间设定为各数据库建库至 2015 年 5 月。剔除重复及不相关文献后, 对纳入文献进行综述。

结论: NGF 作为重要的神经内分泌介质, 可能参与介导了 IBS-D 患者内脏高敏感和肠屏障功能受损, 其在 IBS-D 病理生理学中的作用值得深入研究, 并有望成为治疗靶点。

关键词: 神经生长因子; 腹泻型肠易激综合征; 病理生理学; 内脏高敏感; 肠屏障功能受损